Skip to Content
  • Where MRSA Came From

    OK, everyone recognizes the problem that we face with drug-resistant bacteria. MRSA (methicillin-resistant Staphylococcus aureus) is the most well-known variety… Read More
  • How Long, Oh Lord, How Long?

    Here we have the prototypical slow summer day. So I’m going to use this one to throw a question out to the readership: those of you in preclinical drug di… Read More
  • GSK Rearranges, Once More

    There have been a lot of announcements in the biopharma field this week, and I’m just now getting around to GlaxoSmithKline’s from a couple of days… Read More
  • The Keytruda Story

    This is a good history of Keytruda, the Merck immuno-oncology blockbuster, from David Shaywitz. Most big drugs have a tangled history, and this one is certainly… Read More
  • Following Up

    Here’s a question that I’m not sure if there’s a general answer to: if you’re putting together a drug discovery portfolio, what percenta… Read More
  • China’s Biopharma Rise

    This story by Damien Garde at Stat is well worth a look. It goes into a question that people in biopharma have been asking themselves for some years now: when d… Read More
  • A Look at Antibody Therapies

    Since we were just talking about antibody therapies in immuno-oncology, here’s a timely column by Bruce Booth at LifeSciVC on antibody therapies in genera… Read More
Page 2 of 3912345...102030...Last »